Antibiotics developer Bugworks Research has been backed by Utec in its bid to commercialise a treatment for hospital superbugs.
India-based antibiotics developer Bugworks Research has obtained $9m in a series A round led by University of Tokyo Edge Capital (Utec), an investment vehicle for the institution, YourStory reported yesterday.
Investment firm Acquipharma Holdings also took part in the round alongside 3One4 Capital and unnamed biotech-focused angel investors.
Founded in 2014, Bugworks is developing a group of antibiotics based on its Elude discovery platform to tackle dangerous gram-negative bacterial infections with urgent unmet needs. Such infections cause life-threatening illnesses including…
